The impact of dementia development concurrent with Parkinson’s disease: A new perspective

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 7, 2014, Pages 1160-1168

  Russell, Alyce ^a   Drozdova, Alesya ^a   Wang, Wei ^a   Thomas, Meghan ^a  

^a EDITH COWAN UNIVERSITY   (Australia)

Author keywords

Burden; Comorbidity; Dementia; Epidemiology; Impact; Parkinson s; Progression

Indexed keywords

ALPHA SYNUCLEIN; APOLIPOPROTEIN E; GLUCOSYLCERAMIDASE; LEVODOPA; RIVASTIGMINE; TAU PROTEIN;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; DISEASE CLASSIFICATION; DISEASE COURSE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEALTH CARE COST; HUMAN; INCIDENCE; MENTAL DETERIORATION; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; PARKINSON DISEASE; PREVALENCE; PROTEIN AGGREGATION; QUALITY OF LIFE; RISK FACTOR; BRAIN; COST OF ILLNESS; ECONOMICS; GENETICS; PATHOPHYSIOLOGY;

BRAIN; COST OF ILLNESS; DEMENTIA; HUMANS; PARKINSON DISEASE;

EID: 84911419117     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666140917122739     Document Type: Article

References (87)

1. Alzheimer's Disease International. World Alzheimer's Report: 2009. UK: Kings College London 2009.
2. The World Bank Group. Country and Lending Groups. [04/09/ 2013]; Available from: http://data.worldbank.org/about/countryclassifications/country-and-lending-groups
3. World Health Organisation [WHO]. Dementia: A Public Health Priority. Geneva, Switzerland: World Health Organisation 2012.
4. Dewey ME, Saz P. Dementia, cognitive impairment and mortality in persons aged 65 and over living in the community: a systematic review of the literature. Int J Geriatr Psychiatry 2001; 16(8): 751-61.
5. Wimo A, Jönsson L, Bond J, et al. The worldwide economic impact of dementia 2010. Alzheimer's Dementia 2013; 9(1): 1-11.
6. Koller D, Kaduszkiewicz H, van den Bussche H, et al. Survival in patients with incident dementia compared with a control group: a five-year follow-up. Int Psychogeriatr 2012; 24(9): 1522-30.
7. Rana AQ, Yousuf MS, Naz S, Qa'aty N. Prevalence and relation of dementia to various factors in Parkinson's disease. Psychiatry Clin Neurosci 2012; 66(1): 64-8.
8. Irwin DJ, White MT, Toledo JB, et al. Neuropathologic Substrates of Parkinson's Disease Dementia. Ann Neurol 2012; 72(4): 587-98.
9. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol 2012; 11(8): 697-707.
10. Aarsland D, Zaccai J, Brayne C. A Systematic Review of Prevalence Studies of Dementia in Parkinson's Disease. Movem Disord 2005; 20(10): 1255-63.
11. Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of Nonmotor Symptoms of Parkinson's Disease. Movem Disord 2001; 16(3): 507-10.
12. Meissner WG, Frasier M, Gasser T, et al. Priorities in Parkinson's disease research. Nat Rev 2011; 10(5): 377-93.
13. Bothe MR, Uttner I, Otto M. Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure. J Neural Transm 2010; 117(3): 353-67.
14. Olsen JH, Friis S, Frederiksen K, et al. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2004; 92(1): 201-5.
15. Emre M, Aarsland D, Brown R, et al. Clinical Diagnostic Criteria for Dementia Associated with Parkinson's Disease. Movem Disord 2007; 22(12): 1689-707.
16. Marras C, Zadikoff C, Kennedy N, et al. Measuring mild cognitive impairment in patients with Parkinson's disease. Movem Disord 2013; 28(5): 626-33.
17. Litvan I, Goldman JG, Troster AI, et al. Diagnostic Criteria for Mild Cognitive Impairment in Parkinson's Disease: Movement Disorder Society Task Force Guidelines. Movem Disord 2012; 27(3): 349-56.
18. Reid WGJ, Hely MA, Morris JGL, et al. A longitudinal study of Parkinson's disease: clinical and neuropsychological correlates of dementia. J Clin Neurosci 1996; 3(4): 327-33.
19. de Lau LML, Schnipper MA, Hofman A, Koudstaal PJ, Breteler MMB. Prognosis of Parkinson's Disease. Arch Neurol 2005; 62: 1265-9.
20. Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology 2002; 59(11): 1708-13.
21. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and Characteristics of Dementia in Parkinson's Disease. Arch Neurol 2003; 60: 387-92.
22. Hobson P, Meara J. Risk and Incidence of Dementia in a Cohort of Older Subjects With Parkinson's Disease in the United Kingdom. Movem Disord 2004; 19(9): 1043-9.
23. Riedel O, Klotsche J, Spottke A, et al. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. J Neurol 2008; 255(2): 255-64.
24. Baldivia B, Brucki SMD, Batistela S, et al. Dementia in Parkinson's disease: a Brazilian sample. Arch Neuropsychitr 2011; 69(5): 733-8.
25. Hoegh M, Ibrahim AK, Chibnall J, Zaidi B, Grossberg GT. Prevalence of Parkinson Disease and Parkinson Disease Dementia in Community Nursing Homes. Am J Geriatr Psychiatry 2013; 21(6): 529-35.
26. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson’s disease: A community-based, prospective study. Neurology 2001; 56(6): 730-6.
27. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013; 84(11): 1258-64.
28. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney Multicentre Study of Parkinson's Disease: The Inevitability of Dementia at 20 years. Movem Disord 2008; 23(6): 837-44.
29. Leroi I, McDonald K, Pantula H, Harbishettar V. Cognitive Impairment in Parkinson Disease: Impact on Quality of Life, Disability, and Caregiver Burden. J Geriatr Psychiatry Neurol 2012; 25(4): 208-14.
30. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis. Neurology 2010; 75: 1062-9.
31. Nie K, Zhang Y, Wang L, et al. A pilot study of psychometric properties of the Beijing version of Montreal Cognitive Assessment in patients with idiopathic Parkinson's disease in China. J Clin Neurosci 2012; 19: 1497-500.
32. Gijsen R, Hoeymans N, Schellevis FG, et al. Causes and consequences of comorbidity: A revew. J Clin Epidemiol 2001; 54(7): 661-74.
33. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. J Clin Epidemiol 2003; 56(3): 221-9.
34. World Health Organisation (WHO). The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Researchers. 10th ed. Geneva, Switzerland: World Health Organisation; 1992.
35. World Health Organisation [WHO]. International Classification of Diseases (ICD). 2013 [01/10/2013]; Available from: http://www.who.int/classifications/icd/en/
36. American Psychiatric Association Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Association; 2000.
37. Reisberg B. Diagnostic Criteria in Dementia: A Comparison of Current Criteria, Research Challenges, and Implications for DSMV. J Geriatr Psychiatry Neurol 2006; 19(3): 137-46.
38. Noe E, Marder K, Bell KL, et al. Comparison of Dementia with Lewy Bodies to Alzheimer's Disease and Parkinson's Disease with Dementia. Movem Disord 2004; 19(1): 60-7.
39. Dubois B, Gauthier S, Korczyn A, et al. Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. Movem Disord 2007; 22(16): 2314-24.
40. Barton B, Grabli D, Bernard B, et al. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. Movem Disord 2012; 27(2): 248-53.
41. American Psychiatric Association DSMTF, American Psychiatric A. Diagnostic and statistical manual of mental disorders: DSM-5. Arlington, Va: American Psychiatric Association; 2013.
42. McKhann GM, Mayeux R, Mohs RC, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement 2011; 7(3): 263-9.
43. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996; 47(5): 1113-24.
44. Park KW, Kim HS, Cheon S-M, et al. Dementia with Lewy Bodies versus Alzheimer's Disease and Parkinson's Disease Dementia: A Comparison of Cognitive Profiles. J Clin Neurol 2011; 7(1): 19-24.
45. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J 2009; 339: b2535.
46. Trojanowski JQ, Kenyon L, Bouldin TW. The Nervous System. In: Rubin R, Strayer DS, editors. Rubin's Pathlogy: Clinicopathologic Foundations of Medicine. 5th ed. Baltimore, USA: Lippincott Williams & Wilkins; 2008.
47. Barone P. Neurotransmission in Parkinson's disease: beyond dopamine. Eur J Neurol 2010; 17(3): 364.
48. Goris A, Burn DJ, Chinnery PF, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007; 62(2): 145.
49. Braak H, Bohl JR, Muller CM, et al. Stanley Fahn Lecture 2005: The Staging Procedure for the Inclusion Body Pathology Associated with Sporadic Parkinson's Disease Reconsidered. Movem Disord 2006; 21(12): 2042-51.
50. Braak H, Tredici KD, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24(2): 197-211.
51. Horvath J, Herrmann FR, Burkhard PR, Bouras C, Kövari E. Neuropathology of dementia in a large cohort of patients with Parkinson's disease. Parkinson Relat Disord 2013; 19(10): 864-8.
52. Aarsland D, Beyer MK, Kurz MW. Dementia in Parkinson's Disease. Curr Opin Neurol 2008; 21: 676-82.
53. Goetz CG, Emre M, Dubois B. Parkinson's Disease Dementia: Definitions, Guidelines and Research Perspectives in Diagnosis. Am Neurol Assoc 2008; 64(suppl): S81-92.
54. Jones EL, Aarsland D, Londos E, Ballard C. A pilot study examining associations between DYRK1A and α -synuclein dementias. Neurodegener Dis 2012; 10(1-4): 229.
55. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24: 1121-59.
56. Setó-Salvia N, Clarimón J, Pagonabarraga J, et al. Dementia risk in parkinson disease: Disentangling the role of mapt haplotypes. Arch Neurol 2011; 68(3): 359-64.
57. Morley JF, Chen-Plotkin AS, Van Deerlin V, et al. Genetic influences on cognitive decline in Parkinson's disease. Movem Disord 2012; 27(4): 512-8.
58. Colom-Cadena M, Gelpi E, Martí MJ, et al. MAPT H1 haplotype is associated with enhanced α-synuclein deposition in dementia with Lewy bodies. Neurobiol Aging 2013; 34(3): 936-42.
59. Ding S, Shi J, Qian W, et al. Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A. Neurobiol Aging 2012; 33(7): 1389-99.
60. Wegiel J, Gong C-X, Hwang Y-W. The role of DYRK1A in neurodegenerative diseases. FEBS J 2011; 278(2): 236-45.
61. Goker-Alpan O, Schiffmann R, LaMarca ME, et al. Parkinsonism among Gaucher disease carriers. J Med Genet 2004; 41(12): 937-40.
62. Sidransky E, Brice A, Chen CM, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361(17): 1651-61.
63. Brockmann K, Srulijes K, Hauser A-K, et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011; 77(3): 276-80.
64. Neumann J, Paudel R, Segarane B, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009; 132(7): 1783-94.
65. Setó-Salvia N, Martín I, Muñoz L, et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Movem Disord 2012; 27(3): 393-9.
66. Winder-Rhodes S, Evans JR, Ban M, et al. Glucocerebrosidase mutations influence the natural history of PD in a communitybased incident cohort. Movem Disord 2012; 27: S506-S7.
67. Muller MLTM, Frey KA, Petrou M, et al. B-Amyloid and Postural Instability and Gait Difficulty in Parkinson's Disease at Risk for Dementia. Movem Disord 2013; 28(3): 296-301.
68. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Movem Disord 2006; 21(8): 1123-30.
69. Sellal F. Parkinson's disease with dementia and dementia with Lewy body disease: two syndromes, the same disease? Psychogeriatrics 2006; 6(s1): S30-4.
70. Yarnall AJ, Rochester L, Burn DJ. Mild cognitive impairment in Parkinson's disease. Age Ageing 2013; 0: 1-10.
71. Irwin DJ, Lee VMY, Trojanowski JQ. Parkinson's disease dementia: convergence of [alpha]-synuclein, tau and amyloid-[beta] pathologies. Nat Rev Neurosci 2013; 14(9): 626-36.
72. Williams-Gray CH, Goris A, Saiki M, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease. J Neurol 2009; 256(3): 493-8.
73. Kurz MW, Dekomien G, Nilsen OB, et al. APOE Alleles in Parkinson Disease and Their Relationship to Cognitive Decline: A Population-based, Longitudinal Study. J Geriatr Psychiatry Neurol 2009; 22(3): 166-70.
74. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The Current and Projected Economic Burden of Parkinson's Disease in the United States. Movem Disord 2013; 28(3): 311-8.
75. Vossius C, Larsen JP, Janvin C, Aarsland D. The Economic Impact of Cognitive Impairment in Parkinson's Disease. Movem Disord 2011; 26(8): 1541-4.
76. Gage H, Hendricks A, Zhang S, Kazis L. The relative health related quality of life of veterans with Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74(2): 163-9.
77. International Epidemiological Association. A Dictionary of Epidemiology. 5th ed. New York, USA: Oxford University Press, Inc.; 2008.
78. Leibson CL, Maraganore DM, Bower JH, et al. Comorbid conditions associated with Parkinson's disease: A population-based study. Movem Disord 2006; 21(4): 446-55.
79. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010; 9(12): 1200-13.
80. Chan KY, Wang W, Wu JJ, et al. Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990 - 2010: a systematic review and analysis. Lancet 2013; 381: 2016-23.
81. Prince MJ. Dementia in China: east-west collaboration bears fruit. Lancet 2013; 381: 1967-8.
82. Tolosa E, Martí MJ, Valldeoriola F, Molinuevo JL. History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology 1998; 50(6 Suppl 6): S2-10.
83. Chitnis S, Rao J. Rivastigmine in Parkinson's Disease Dementia. Expert Opin Drug Metab Toxicol 2009; 5(8): 941-55.
84. Modi G, Pillay V, Choonara YE. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann NY Acad Sci 2010; 1184(1): 154.
85. Pehlivan SB. Nanotechnology-Based Drug Delivery Systems for Targeting, Imaging and Diagnosis of Neurodegenerative Diseases. Pharm Res 2013: 1-13.
86. Paxinos G, Watson C. The Rat Brain Stereotaxic Coordinates. 7th ed. San Diego, USA: Elsevier Academic Press; 2007.
87. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Tredici KD. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404.